Tamoxifen Benefit Durable

December 12, 2014 4:03 PM

3 0

SAN ANTONIO -- Tamoxifen's primary prevention benefits continue to accrue long-term, reaching a number needed to treat of just 22 at two decades of follow-up in the IBIS-I trial.

Incidence of any breast cancer was 7.8% with a 5-year course of the anti-estrogen treatment compared with 12.3% in the placebo group of the trial (P<0.0001), Jack Cuzick, PhD, of Queen Mary University London, and colleagues found in the IBIS-I trial at 20 years.

Read more

To category page